Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB) develops and sells life science research instruments, consumables, reagents and services that support proteomic and genomic analysis for academic and translational research institutions, clinical research laboratories, and biopharmaceutical, biotechnology, and plant and animal… From the company’s description.
Over the twelve months to Sep 30, 2026, Standard BioTools Inc. reported revenue of $84.43M and net income of $133.08M. Its operating margin was −97.5%, and operations used $64.26M in cash. In fiscal 2025, it reported revenue of $85.33M and a net loss of $74.90M.
Dotted labels explain each measure. is shown separately from the annual figures.
What Standard BioTools Inc. does
In the company’s own words
Standard BioTools Inc. (Nasdaq: LAB) develops and sells life science research instruments, consumables, reagents and services that support proteomic and genomic analysis for academic and translational research institutions, clinical research laboratories, and biopharmaceutical, biotechnology, and plant and animal research companies. Its continuing platforms include CyTOF mass cytometry for high-parameter single-cell analysis, Hyperion Imaging Mass Cytometry for spatial protein analysis in tissue, and Biomark microfluidic systems for high-throughput qPCR and genomic studies. The company also collaborates with original equipment manufacturers using its microfluidics technology. Its SomaScan aptamer-based proteomics business was sold to Illumina in January 2026; the retained business focuses on mass cytometry and microfluidics. Products include the CyTOF XT, Hyperion, Biomark X9, Maxpar reagents, and Integrated Fluidic Circuits. Standard BioTools reported revenue of $84.9 million for fiscal 2025 and had 389 employees worldwide at year-end, excluding discontinued operations. Its website is www.standardbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1162194
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Standard BioTools Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Standard BioTools Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Standard BioTools Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Standard BioTools Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Standard BioTools Inc.'s last four quarterly filings that the numbers alone won't show?”